



A Discussion of Time to Benefit and Harm of Direct Oral Anticoagulants in Device-Detected Atrial Fibrillation: A Pooled Analysis of the NOAH-AFNET 6 and ARTESiA Trials

Hosted by William H. Sauer, MD, FHRS, CCDS

Article Information:

Article for Discussion: [Time to Benefit and Harm of Direct Oral Anticoagulants in Device-Detected Atrial Fibrillation: A Pooled Analysis of the NOAH-AFNET 6 and ARTESiA Trials](#)

Authors: Chuanyi Huang, BS, Linjie Li, MD, Wennan Liu, MD, Yiwen Fang, MD, Shichen Jiang, MD, Yongle Li, MD, PhD, Gregg C. Fonarow, MD, Ching-Hui Sia, MBBS, MRCP, Leonard L.L. Yeo, PhD, MRCP, Benjamin Y.Q. Tan, MBBS, MRCP, Gregory Y.H. Lip, MD, Qing Yang, MD, PhD, Xin Zhou, MD, PhD, FACC

Publication: Journal of the American College of Cardiology: Clinical Electrophysiology




Today's Host



William H. Sauer, MD, FHRF, CCDS
Brigham and Women's Hospital



Today's Contributors:



Rod S. Passman, MD, FHRF
Northwestern University



Graham Peigh, MD, MS
Northwestern Memorial Hospital



Disclosures:

William H. Sauer, MD, FHRS, CCDS

- **Honoraria/Speaking/Consulting: Biotronik, Biosense Webster, Inc., Abbott, Boston Scientific**
- **Research: Medtronic**

Rod S. Passman, MD, FHRS

- **Research: AHA Foundation Award, Abbott Medical, NIH/NHLBI, Apple Inc.**
- **Royalty Income: UpToDate, Inc**
- **Honoraria/Speaking/Consulting: Janssen Pharmaceuticals, Boston Scientific**
- **Membership on Advisory Committees: Medtronic, iRhythm Technologies**

Graham Peigh, MD, MS

- **Nothing to disclose.**





Thank you!